ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
9 July 2025
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
30 June 2025
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
30 June 2025
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
26 June 2025
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
26 June 2025
The company reckons its immunotherapy could improve on Keytruda.